Nurix Inc.
www.nurix-inc.com
Latest From Nurix Inc.
Deal Watch: Gilead Partners With Carna On Small Molecule IO Drug Development
Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.
Deal Watch: Sanofi Further Opts Out Of CNS Tie-Up With Voyager
Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with Bristol, while Ultragenyx and Arcturus expand their joint rare disease efforts.
Gilead Dives Into Protein Degradation With Nurix Pact
Gilead is elbowing its way into the protein degradation field, seeking to build out a pipeline of oncology drugs in a $45m deal with Nurix. The pool is becoming crowded though, as many other big firms have latched onto this burgeoning field of R&D.
Celgene Further Commits To Neuroscience With Prothena Pact
It is a risky business but the biotech major is paying $150m upfront, and potentially hundreds of millions of dollars more, to work with Prothena and develop therapies targeted at proteins implicated in highly challenging neurodegenerative diseases such as Alzheimer's and ALS.
Company Information
- Industry
-
Biotechnology
- Drug Discovery Tools
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Nurix Inc.
- Senior Management
-
Arthur T Sands, MD, PhD, CEO
Nancy Pryer, PhD, Chief Dev. Officer
Pierre Beaurang, PhD, CBO
Hans van Houte, VP, Finance - Contact Info
-
Nurix Inc.
Phone: (415) 660-5320
1700 Owens St.
Ste. 205
San Francisco, CA 94158
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice